Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI105786

In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and Gdmediterranean deficiency

Sergio Piomelli, Laurence M. Corash, Deatra D. Davenport, Janet Miraglia, and Edward L. Amorosi

Department of Pediatrics, New York University School of Medicine, New York

Find articles by Piomelli, S. in: PubMed | Google Scholar

Department of Pediatrics, New York University School of Medicine, New York

Find articles by Corash, L. in: PubMed | Google Scholar

Department of Pediatrics, New York University School of Medicine, New York

Find articles by Davenport, D. in: PubMed | Google Scholar

Department of Pediatrics, New York University School of Medicine, New York

Find articles by Miraglia, J. in: PubMed | Google Scholar

Department of Pediatrics, New York University School of Medicine, New York

Find articles by Amorosi, E. in: PubMed | Google Scholar

Published April 1, 1968 - More info

Published in Volume 47, Issue 4 on April 1, 1968
J Clin Invest. 1968;47(4):940–948. https://doi.org/10.1172/JCI105786.
© 1968 The American Society for Clinical Investigation
Published April 1, 1968 - Version history
View PDF
Abstract

A decreased level of glucose-6-phosphate dehydrogenase might result from decreased rate of synthesis, synthesis of an enzyme of lower catalytic efficiency, increased lability, or a combined mechanism. To test the hypothesis of increased lability, the rate of decline of the enzyme in vivo was measured in three groups of individuals, controls, Gd(—),A-males, and Gd(—), Mediterranean males, by the slope of decline of activity in fractions containing erythrocytes of progressively increasing mean age. These fractions were obtained by ultracentrifugation on a discontinuous density gradient of erythrocyte suspensions free of contaminating platelets and leukocytes.

The rate of in vivo decline of pyruvate kinase (another age-dependent enzyme) was also measured and found very similar in the three groups.

The in vivo decline of glucose-6-phosphate dehydrogenase was found to follow an exponential rate, with a half-life of 62 days for controls and 13 days for Gd(—),A- erythrocytes. The activity in normal reticulocytes was estimated at 9.7 U and in Gd(—),A- reticulocytes at 8.8 U. These estimates were confirmed by direct measurements in reticulocytes isolated from patients with extreme reticulocytosis.

In Gd(—),Mediterranean erythrocytes activity could be demonstrated only in reticulocytes, which were estimated to average 1.4 U. The rate of decline is so extreme that no activity could be detected in mature erythrocytes.

These data suggest that the glucose-6-phosphate dehydrogenase deficiency of both the GdA- and the GdMediterranean variant results from different degrees of in vivo instability of the abnormal enzyme.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 940
page 940
icon of scanned page 941
page 941
icon of scanned page 942
page 942
icon of scanned page 943
page 943
icon of scanned page 944
page 944
icon of scanned page 945
page 945
icon of scanned page 946
page 946
icon of scanned page 947
page 947
icon of scanned page 948
page 948
Version history
  • Version 1 (April 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts